{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:47:39Z","timestamp":1789091259782,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515011182"],"award-info":[{"award-number":["2021A1515011182"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012272"],"award-info":[{"award-number":["2022A1515012272"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903037"],"award-info":[{"award-number":["81903037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072029"],"award-info":[{"award-number":["82072029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.eclinm.2022.101625","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T21:23:47Z","timestamp":1661549027000},"page":"101625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial"],"prefix":"10.1016","volume":"53","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-8596","authenticated-orcid":false,"given":"Chengtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2773-4130","authenticated-orcid":false,"given":"Yulin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3891-2721","authenticated-orcid":false,"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eclinm.2022.101625_bib0001","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5732\/cjc.009.10329","article-title":"Is nasopharyngeal cancer really a \u201cCantonese cancer\u201d?","volume":"29","author":"Wee","year":"2010","journal-title":"Chin J Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101625_bib0002","first-page":"313","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"70","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101625_bib0003","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomised Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2022.101625_bib0004","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.03.015","article-title":"Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: an analysis of 614 patients from a single center","volume":"69","author":"Wu","year":"2017","journal-title":"Oral Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101625_bib0005","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2005.12.081","article-title":"Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials","volume":"23","author":"Chua","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101625_bib0006","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomised phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"27","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101625_bib0007","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomised controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2022.101625_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial","volume":"75","author":"Cao","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2022.101625_bib0009","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101625_bib0010","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese society of clinical oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.eclinm.2022.101625_bib0011","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf."},{"issue":"53","key":"10.1016\/j.eclinm.2022.101625_bib0012","doi-asserted-by":"crossref","first-page":"91150","DOI":"10.18632\/oncotarget.20017","article-title":"Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma","volume":"8","author":"Fangzheng","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101625_bib0013","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/cncr.29795","article-title":"Proposal for the 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy","volume":"122","author":"Pan","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101625_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101625_bib0015","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101625_bib0016","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101625_bib0017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","article-title":"Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial","volume":"19","author":"Tang","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101625_bib0018","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101625_bib0019","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomised trials","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101625_bib0020","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.18632\/oncotarget.14279","article-title":"Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.eclinm.2022.101625_bib0021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1017\/S0022215116008513","article-title":"Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study","volume":"130","author":"Noronha","year":"2016","journal-title":"J Laryngol Otol"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101625_bib0022","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00280-009-1152-0","article-title":"Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer","volume":"65","author":"Bae","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101625_bib0023","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomised controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2022.101625_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.765378","article-title":"Efficacy and toxicity of three induction chemotherapy regimens in locoregionally advanced nasopharyngeal carcinoma: outcomes of 10-year follow-up","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2022.101625_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.731543","article-title":"Comparison of TPF and TP induction chemotherapy for locally advanced nasopharyngeal carcinoma based on TNM stage and pretreatment systemic immune-inflammation index","volume":"11","author":"Xiong","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2022.101625_bib0026","first-page":"581","article-title":"Epstein-Barr virus and nasopharyngeal carcinoma","volume":"33","author":"Young","year":"2014","journal-title":"Chin J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101625_bib0027","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","article-title":"Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma","volume":"10","author":"Lv","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101625_bib0028","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12885-020-6555-7","article-title":"Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.eclinm.2022.101625_bib0029","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101625_bib0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5732\/cjc.009.10367","article-title":"Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma","volume":"29","author":"Guo","year":"2010","journal-title":"Chin J Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022003558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022003558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:23:15Z","timestamp":1781817795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022003558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"alternative-id":["S2589537022003558"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101625","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101625"}}